the value of axi-cel as a second-line treatment in r/r lbcl
Published 2 months ago • 40 plays • Length 2:45Download video MP4
Download video MP3
Similar videos
-
1:13
second-line treatment strategies for patients with relapsed dlbcl
-
3:33
a novel composite endpoint of toxicity and pfs in patients with r/r fl treated with axi-cel
-
2:05
cd58 aberrations correlate with poor response to axi-cel in lbcl
-
3:53
standard-of-care setting results of axi-cel in r/r large b-cell lymphoma
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
4:14
a pilot study of axi-cel in primary and secondary cns lymphomas
-
24:46
sumit verma of iovance biotherapeutics - 1 time therapy for solid tumors
-
5:00
diagnosing and treating al amyloidosis: a 2020 update from dr morie gertz
-
9:25
mgus diagnosis: a step-by-step approach
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
3:10
is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for mcl?
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
1:52
results of phase i study of mcl-1 inhibition with azd5991 in r/r hematologic malignancies
-
2:59
low-intensity venetoclax-based preconditioning followed by sequential allosct for r/r aml or hr-mds
-
4:45
safety and efficacy of obe-cel in r/r adult b-all: results of the pivotal felix study
-
2:41
an overview of the latest advances in hematology
-
2:42
results from a phase i study of cc-98633 in r/r myeloma
-
3:46
the impact of cytogenetic risk on outcomes of haploidentical transplantation in r/r aml
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:19
anbal-cel: updated results from phase i study of novel cd19-targeting car-t therapy
-
1:41
addressing diversity, equity, and inclusion in hematology clinical trials across europe